FDA Questions Safety Of Cephalon's Sparlon

The Food and Drug Adminstration released reports questioning the safety of Cephalon Inc.'s (CEPH) Sparlon drug for treating attention deficit hyperactivity disorder. Sparlon is currently marketed as sleep disorder medication under the name Provigil. The stock price rose $1.45 to clost at $73.31.